WO1993008768A1 - Silicone/dacron composite vascular graft - Google Patents

Silicone/dacron composite vascular graft Download PDF

Info

Publication number
WO1993008768A1
WO1993008768A1 PCT/US1992/009359 US9209359W WO9308768A1 WO 1993008768 A1 WO1993008768 A1 WO 1993008768A1 US 9209359 W US9209359 W US 9209359W WO 9308768 A1 WO9308768 A1 WO 9308768A1
Authority
WO
WIPO (PCT)
Prior art keywords
silicone
porous
graft
layer
bead
Prior art date
Application number
PCT/US1992/009359
Other languages
French (fr)
Inventor
Mark D. Stenoien
William J. Drasler
Robert J. Scott
Mark L. Jenson
Original Assignee
Possis Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Possis Medical, Inc. filed Critical Possis Medical, Inc.
Priority to AU30591/92A priority Critical patent/AU672588B2/en
Priority to JP5508635A priority patent/JPH07505789A/en
Priority to EP92924189A priority patent/EP0662805A1/en
Publication of WO1993008768A1 publication Critical patent/WO1993008768A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/924Material characteristic
    • Y10S623/926Synthetic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/13Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352Polymer or resin containing [i.e., natural or synthetic]
    • Y10T428/1369Fiber or fibers wound around each other or into a self-sustaining shape [e.g., yarn, braid, fibers shaped around a core, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/13Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352Polymer or resin containing [i.e., natural or synthetic]
    • Y10T428/1376Foam or porous material containing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/13Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352Polymer or resin containing [i.e., natural or synthetic]
    • Y10T428/139Open-ended, self-supporting conduit, cylinder, or tube-type article
    • Y10T428/1393Multilayer [continuous layer]

Definitions

  • the present invention pertains to a silicone/DACRON® composite vascular graft, especially well suited as an arteriovenous (A-V) graft fistula for patients requiring long-term vascular access, such as in the case of chronic kidney dialysis.
  • A-V arteriovenous
  • the general purpose of the present invention is to provide a silicone/DACRON composite vascular graft for use as an artificial blood vessel, especially an arteriovenous (A-V) graft fistula providing long-term vascular access for kidney dialysis applications.
  • A-V arteriovenous
  • a graft including a non-porous, smooth inner blood contact surface which reduces thrombus deposition; a silicone bead spiral or ring for anti-kink and anti-crush; a DACRON wind primarily for added strength; a small pore bulk construction with an impermeable inner surface which reduces fibroblast ingrowth and helps maintain compliance; continued elasticity allows excellent needle puncture sealing immediately and over time without applying external pressure; and the DACRON wind is coated with silicone to prevent body tissue from contacting DACRON which is a very thrombogenic material.
  • the use of IR energy partially cures the silicone strand before it contacts the mandrel; the order of construction of the graft enhances the strength, anti-crush, and anti-kink; the angle of applying the DACRON yarn and placement on top of the silicone bead allows the DACRON filaments to move relative to its repeat unit neighbor to help reduce any tendency toward graft kinking; and the silicone is dispersed in solvent for electrostatic spinning.
  • the blood contacting surface of the graft can be of a fibrous porous construction, similar but not necessarily identical, in structure to the middle and outer porous structure of the first embodiment.
  • the pore size may range from approximately 2 microns to 100 microns.
  • the porous inner surface will allow cellular attachment to the inside surface of the graft. These cells may originate from cells located at the junction of the graft with the native vessel, from cells that grow through the walls of the graft from the outside tissue or from the blood itself.
  • the porous inner surface may enhance long term patency of the graft in vascular grafting situations where the blood flow rate is relatively low.
  • the graft can be constructed without the DACRON yarn filament.
  • the function of the graft will be suitable for most vascular graft applications; the strength of the graft to resist aneurysm or suture pullout x-zill be somewhat reduced.
  • the significant aspects, advantages and uniqueness of this graft in summary are: 1) the non-porous smooth silicone blood contact surface, which reduces thrombus deposit; 2) the bulk pore size and the solid inner surface, results in needle puncture sealing immediately and over time without applying external pressure; 3) the use of IR energy along with electrostatic spinning; 4) the application of a silicone bead for anti-kink and anti-crush; 5) the application of DACRON yarn for strength, without any significant reduction in anti-kink properties of the graft; 6) the coating of the DACRON yarn with silicone prior to its application onto the graft; and 7) the bulk pore size and solid inner surface which tends to allow reticulocyte penetration into the porous portion of the graft, but not much fibroblastic ingrowth, results in retaining graft compliance or elasticity over time.
  • Another significant aspect and feature of the process is construction which uses electrostatic spinning or spraying technology to form a fibrous and porous silicone structure that is found in much of the graft wall.
  • This electrostatic technology is also used to apply the non-porous smooth silicone layer directly onto a mandrel and form the blood contact surface after removal of the graft from the mandrel.
  • FIG. 1 illustrates a plan view of a vascular graft
  • FIG. 2 illustrates a partial cross-sectional view of FIG. 1
  • FIG. 3 illustrates a first alternative embodiment
  • FIG. 4 illustrates a second alternative embodiment
  • FIG. 1 illustrates a plan view of the graft 10.
  • FIG. 2 illustrates a partial cross-sectional view of FIG. 1.
  • a meld layer 12 is first applied to a mandrel spinning at low rpm (approximately 200 rpm) with IR heater off, but with the electrostatic spinning voltages of the grid and mandrel activated. This allows a uniform layer of silicone to be deposited onto the mandrel forming a blood contact surface that is as smooth as the mandrel finish and impermeable to blood, plasma, or cellular penetration. The high flow rate of blood which will move through the graft 10 will help prevent thrombus deposition on the smooth surface.
  • this graft 10 does not require preclotting (a method required for some porous grafts whereby blood is allowed to clot within the graft wall to prevent seepage or bleeding through the graft walls).
  • This non-porous inner meld layer 12 also reduces the amount of fibroblastic cell penetration into the graft 10 from the outside surface. Fibroblastic ingrowth generally results in the deposition of collagen within the pores of porous grafts and significantly reduces the flexibility of the graft 10 over time. The reduction in fibroblastic ingrowth into the walls of this graft 10 allows it to remain flexible and thereby maintain its needle puncture hole sealing characteristic, as well as its flexibility and anti-kink properties.
  • the mandrel is spun at a much faster rate (approximately 4000 rpm).
  • the IR heater and the electrostatic voltages are both activated.
  • the fibers are partially cured before they contact the mandrel due to the application of IR energy.
  • the porosity of this layer can be controlled by adjusting the amount of fiber cure prior to deposition onto the mandrel.
  • This layer provides fibrous structure of the graft 10 which serves as a framework to hold the silicone bead 16 and DACRON yarn 18 that is applied on top of it, and to allow a structure that can expand and compress, and thereby contribute to the anti-kink character of the graft 10.
  • This layer also contributes to graft strength and needle puncture sealing.
  • the pore spacing and silicone fiber diameter range from 2 to 100 microns with a generally random occurrence.
  • the pore size is of appropriate size to allow reticulocyte penetration into the graft wall, but not so large as to allow entry access to significant fibroblast penetration.
  • Reticulocytes are cells which can penetrate into the small pore spaces, but generally do not deposit significant collagenous material that can result in loss of graft elasticity and needle hole sealing characteristics.
  • a silicone bead 16 is then applied in a noncured form in a spiral configuration onto the porous middle layer 14 of the graft 10. This step is not done using electrostatics and involves simply extruding a silicone bead 16 onto a rotating graft 10 while moving transversely to form a spiral; the silicone bead 16 is then partially cured afterward.
  • This spiral silicone bead 16 serves to enhance the graft 10 anti-kink and anti-crush properties by providing a structure which tends to maintain a circular cross section in the graft under compressive forces and forces which are generated when the graft 10 is bent to a radius of curvature of 1 cm or less.
  • This spiral silicone bead 16 could be replaced with a series of torus shaped rings spaced approximately as far apart as each repeat unit of the spiral.
  • a polyethylene terethalate (PET) or DACRON winding 18 is applied forming a series of spirals which are wound with both right handedness and left handedness winding directions.
  • PET polyethylene terethalate
  • DACRON winding 18 provides strength to the graft 10 so that the graft 10 does not exhibit weakness axially or radially with resultant aneurysm formation.
  • the DACRON fibers also contribute to enhance the pullout strength for sutures at the ends of the graft 10 where they are sewn to native vessels.
  • the positioning of the DACRON winding 18 over the silicone bead 16 allows the graft 10 to maintain excellent anti-kink characteristics.
  • Each DACRON strand can change its relative position to its neighboring repeat strand while the graft 10 is being bent, and thereby not inhibit bending.
  • the presence of the DACRON strands in the graft wall tend to resist the formation of an oval cross section of the graft 10, and thereby contribute to enhanced anti-kink and anti-crush characteristics for the graft 10.
  • the DACRON could be replaced by other biostable filamentous materials.
  • the DACRON yarn is coated with silicone prior to its application onto the graft 10 to insure that DACRON material is not put into direct contact with body tissue and to enhance DACRON to graft bonding..
  • the outer silicone layer 20 is applied using ELS spinning and IR energy. It provides a porous outer layer that allows tissue to ingrow and anchor it in place in the subcutaneous tissue of the patient. It also helps to hold the DACRON winding 18 and silicone bead 16 in place.
  • the pore structure is similar to the middle porous layer and retains its elasticity due to minimal fibroblastic ingrowth.
  • the graft can be constructed in a manner identical with that of the preferred embodiment, however with an additional porous silicone inner layer that is first applied onto the mandrel.
  • This inner layer 22 will allow tissue to attach to the graft inner surface.
  • a meld layer would then be applied second and would serve to prevent blood or plasma penetration through the graft wall.
  • the graft is constructed in a manner identical to that of the preferred embodiment with the omission of the inner meld layer 12.
  • the inner surface consists of porous silicone fibers to allow good tissue attachment on the inner surface.
  • the meld layer is not present and tissue can penetrate through the entire wall of the graft from the outside of the graft to the inner surface.
  • the graft can be constructed of another biostable polymeric material, other than silicone, that can be spun electrostatically.
  • the PET filament can be replaced by another biostable filament to provide additional graft strength.
  • the silicone bead can be replaced by another biostable polymeric material that can be bound to silicone, and provide the anti-kink characteristics of the graft.

Abstract

A silicone/DACRON (16, 18) composite vascular graft (10) especially well suited as an arteriovenous (A-V) graft fistula for dialysis application. Distinct uniquenesses include the ability to seal around needle puncture holes without externally applied pressure, excellent anti-kink, anti-crush and strength properties, and a smooth non-porous inner surface which reduces thrombus deposition and enhances the graft wall compliance or elasticity.

Description

SILICONE/DACRON COMPOSITE VASCULAR GRAFT
CROSS REFERENCES TO CO-PENDING APPLICATIONS
None.
BACKGROUND OF THE INVENTION
1. Field of tae Invention - The present invention pertains to a silicone/DACRON® composite vascular graft, especially well suited as an arteriovenous (A-V) graft fistula for patients requiring long-term vascular access, such as in the case of chronic kidney dialysis.
2. Description of the Prior Art - Other silicone grafts have been developed in the past using a variety of construction methods. The benefits of silicone material were described in U.S. Patent 4,687,482. A DACRON outer support, which prevents aneurysm is described in U.S. Patent Nos. 4,657,544 and 4,629,458. White and Roy have patents which use silicone impregnated into sea urchin skeleton to form a porous structure once the skeleton is dissolved away in U.S. Patent Nos. 3,890,107 and 3,929,971.
An electrostatic spinning technology has been patented for use in primarily polyurethane grafts in U.S. Patent Nos. 4,043,331; 4,044,404; 4,639,186; 4,127,706; 4,345,414; 4,323,525; and 4,878,908. These patents were used to spin polyurethane fibers. Without the addition of Infra Red (IR) curing as part of the immediate fiber curing process, the silicone fibers would meld together and form a clump.
SUMMARY OF THE INVENTION
The general purpose of the present invention is to provide a silicone/DACRON composite vascular graft for use as an artificial blood vessel, especially an arteriovenous (A-V) graft fistula providing long-term vascular access for kidney dialysis applications.
According to one embodiment of the present invention, there is provided a graft including a non-porous, smooth inner blood contact surface which reduces thrombus deposition; a silicone bead spiral or ring for anti-kink and anti-crush; a DACRON wind primarily for added strength; a small pore bulk construction with an impermeable inner surface which reduces fibroblast ingrowth and helps maintain compliance; continued elasticity allows excellent needle puncture sealing immediately and over time without applying external pressure; and the DACRON wind is coated with silicone to prevent body tissue from contacting DACRON which is a very thrombogenic material.
According to the process for the embodiment of the present invention, the use of IR energy partially cures the silicone strand before it contacts the mandrel; the order of construction of the graft enhances the strength, anti-crush, and anti-kink; the angle of applying the DACRON yarn and placement on top of the silicone bead allows the DACRON filaments to move relative to its repeat unit neighbor to help reduce any tendency toward graft kinking; and the silicone is dispersed in solvent for electrostatic spinning.
In another embodiment of the present invention, the blood contacting surface of the graft can be of a fibrous porous construction, similar but not necessarily identical, in structure to the middle and outer porous structure of the first embodiment. The pore size may range from approximately 2 microns to 100 microns. The porous inner surface will allow cellular attachment to the inside surface of the graft. These cells may originate from cells located at the junction of the graft with the native vessel, from cells that grow through the walls of the graft from the outside tissue or from the blood itself. The porous inner surface may enhance long term patency of the graft in vascular grafting situations where the blood flow rate is relatively low.
In yet another embodiment of the present invention, the graft can be constructed without the DACRON yarn filament. The function of the graft will be suitable for most vascular graft applications; the strength of the graft to resist aneurysm or suture pullout x-zill be somewhat reduced. The significant aspects, advantages and uniqueness of this graft in summary are: 1) the non-porous smooth silicone blood contact surface, which reduces thrombus deposit; 2) the bulk pore size and the solid inner surface, results in needle puncture sealing immediately and over time without applying external pressure; 3) the use of IR energy along with electrostatic spinning; 4) the application of a silicone bead for anti-kink and anti-crush; 5) the application of DACRON yarn for strength, without any significant reduction in anti-kink properties of the graft; 6) the coating of the DACRON yarn with silicone prior to its application onto the graft; and 7) the bulk pore size and solid inner surface which tends to allow reticulocyte penetration into the porous portion of the graft, but not much fibroblastic ingrowth, results in retaining graft compliance or elasticity over time.
Another significant aspect and feature of the process is construction which uses electrostatic spinning or spraying technology to form a fibrous and porous silicone structure that is found in much of the graft wall. This electrostatic technology is also used to apply the non-porous smooth silicone layer directly onto a mandrel and form the blood contact surface after removal of the graft from the mandrel. BRIEF DESCRIPTION OF THB DRAWINGS
Other objects of the present invention and many of the attendant advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, in which like reference numerals designate like parts throughout the figures thereof and wherein:
FIG. 1 illustrates a plan view of a vascular graft;
FIG. 2 illustrates a partial cross-sectional view of FIG. 1;
FIG. 3 illustrates a first alternative embodiment; and,
FIG. 4 illustrates a second alternative embodiment.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
FIG. 1 illustrates a plan view of the graft 10.
FIG. 2 illustrates a partial cross-sectional view of FIG. 1. A meld layer 12 is first applied to a mandrel spinning at low rpm (approximately 200 rpm) with IR heater off, but with the electrostatic spinning voltages of the grid and mandrel activated. This allows a uniform layer of silicone to be deposited onto the mandrel forming a blood contact surface that is as smooth as the mandrel finish and impermeable to blood, plasma, or cellular penetration. The high flow rate of blood which will move through the graft 10 will help prevent thrombus deposition on the smooth surface. Since blood or plasma cannot penetrate this layer, this graft 10 does not require preclotting (a method required for some porous grafts whereby blood is allowed to clot within the graft wall to prevent seepage or bleeding through the graft walls). This non-porous inner meld layer 12 also reduces the amount of fibroblastic cell penetration into the graft 10 from the outside surface. Fibroblastic ingrowth generally results in the deposition of collagen within the pores of porous grafts and significantly reduces the flexibility of the graft 10 over time. The reduction in fibroblastic ingrowth into the walls of this graft 10 allows it to remain flexible and thereby maintain its needle puncture hole sealing characteristic, as well as its flexibility and anti-kink properties.
The next layer, which is applied on top of the non-porous meld layer 12, is the porous silicone middle layer 14. To form individual fibers the mandrel is spun at a much faster rate (approximately 4000 rpm). The IR heater and the electrostatic voltages are both activated. The fibers are partially cured before they contact the mandrel due to the application of IR energy. The porosity of this layer can be controlled by adjusting the amount of fiber cure prior to deposition onto the mandrel. This layer provides fibrous structure of the graft 10 which serves as a framework to hold the silicone bead 16 and DACRON yarn 18 that is applied on top of it, and to allow a structure that can expand and compress, and thereby contribute to the anti-kink character of the graft 10. This layer also contributes to graft strength and needle puncture sealing. The pore spacing and silicone fiber diameter range from 2 to 100 microns with a generally random occurrence. The pore size is of appropriate size to allow reticulocyte penetration into the graft wall, but not so large as to allow entry access to significant fibroblast penetration. Reticulocytes are cells which can penetrate into the small pore spaces, but generally do not deposit significant collagenous material that can result in loss of graft elasticity and needle hole sealing characteristics.
A silicone bead 16 is then applied in a noncured form in a spiral configuration onto the porous middle layer 14 of the graft 10. This step is not done using electrostatics and involves simply extruding a silicone bead 16 onto a rotating graft 10 while moving transversely to form a spiral; the silicone bead 16 is then partially cured afterward. This spiral silicone bead 16 serves to enhance the graft 10 anti-kink and anti-crush properties by providing a structure which tends to maintain a circular cross section in the graft under compressive forces and forces which are generated when the graft 10 is bent to a radius of curvature of 1 cm or less. This spiral silicone bead 16 could be replaced with a series of torus shaped rings spaced approximately as far apart as each repeat unit of the spiral.
On top of the silicone bead, a polyethylene terethalate (PET) or DACRON winding 18 is applied forming a series of spirals which are wound with both right handedness and left handedness winding directions. The presence of the DACRON winding 18 provides strength to the graft 10 so that the graft 10 does not exhibit weakness axially or radially with resultant aneurysm formation. The DACRON fibers also contribute to enhance the pullout strength for sutures at the ends of the graft 10 where they are sewn to native vessels. The positioning of the DACRON winding 18 over the silicone bead 16 allows the graft 10 to maintain excellent anti-kink characteristics. Each DACRON strand can change its relative position to its neighboring repeat strand while the graft 10 is being bent, and thereby not inhibit bending. In addition, the presence of the DACRON strands in the graft wall tend to resist the formation of an oval cross section of the graft 10, and thereby contribute to enhanced anti-kink and anti-crush characteristics for the graft 10. The DACRON could be replaced by other biostable filamentous materials. Currently, the DACRON yarn is coated with silicone prior to its application onto the graft 10 to insure that DACRON material is not put into direct contact with body tissue and to enhance DACRON to graft bonding..
The outer silicone layer 20 is applied using ELS spinning and IR energy. It provides a porous outer layer that allows tissue to ingrow and anchor it in place in the subcutaneous tissue of the patient. It also helps to hold the DACRON winding 18 and silicone bead 16 in place. The pore structure is similar to the middle porous layer and retains its elasticity due to minimal fibroblastic ingrowth.
DESCRIPTION OF THE ALTERNATIVE EMBODIMENTS
The graft can be constructed in a manner identical with that of the preferred embodiment, however with an additional porous silicone inner layer that is first applied onto the mandrel. This inner layer 22 will allow tissue to attach to the graft inner surface. A meld layer would then be applied second and would serve to prevent blood or plasma penetration through the graft wall.
In yet another embodiment, the graft is constructed in a manner identical to that of the preferred embodiment with the omission of the inner meld layer 12. With this construction, the inner surface consists of porous silicone fibers to allow good tissue attachment on the inner surface. In this case, the meld layer is not present and tissue can penetrate through the entire wall of the graft from the outside of the graft to the inner surface.
In yet another embodiment, the graft can be constructed of another biostable polymeric material, other than silicone, that can be spun electrostatically.
In yet another embodiment, the PET filament can be replaced by another biostable filament to provide additional graft strength.
In yet another embodiment, the silicone bead can be replaced by another biostable polymeric material that can be bound to silicone, and provide the anti-kink characteristics of the graft.
Various modifications can be made to the present invention without departing from the apparent scope hereof. There can be a coating or layer of the porous silicone middle layer material between the silicone bead and the polyethylene terethalate winding, although this is optional.
WE CLAIM:

Claims

1. A composite graft comprising in order:
a. a non-porous meld inner layer of silicone;
b. a porous silicone middle layer;
c. a silicone bead;
d. a polyethylene terethalate winding; and, e. a porous silicone outer layer.
2. A composite graft comprising in order:
a. a porous silicone inner layer;
b. a porous silicone middle layer which may vary in pore size from the inner layer;
c. a silicone bead;
d. a PET winding; and,
e. a porous silicone outer layer.
3. Composite graft comprising in order:
a. a porous silicone inner layer;
b. a non-porous meld layer;
c. a porous silicone middle layer;
d. a silicone bead;
e. a PET winding; and,
f. a porous silicone outer layer.
4. Composite graft comprising in order:
a. a non-porous smooth polymeric meld layer;
b. a porous polymeric middle layer;
c. a polymeric bead;
d. a polymeric winding; and,
e. a porous polymeric outer layer.
5. A method of constructing a composite graft comprising in order:
a. spraying a non-porous meld inner layer of silicone unto a rotating mandrel;
b. electrostatically spinning silicone fibers, which have been partially cured using infrared energy onto rotating mandrel with partial graft;
c. extruding a silicone bead onto a rotating mandrel with partial graft while moving transversely;
d. winding a silicone coated non-static biocompatible thread in both right handedness and left handedness directions onto rotating mandrel with partial graft;
e. electrostatically spinning silicone fibers, which have been partially cured using infrared energy onto rotating mandrel with partial graft; and,
f. dispersing the silicone in a suitable solvent for electrostatic spinning.
6. A method of controlling the porosity or percent void fraction in a porous silicone structure by controlling the amount of partial cure of the fibers and amount of melding of fiber prior to their deposition onto the mandrel.
PCT/US1992/009359 1991-11-04 1992-10-27 Silicone/dacron composite vascular graft WO1993008768A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU30591/92A AU672588B2 (en) 1991-11-04 1992-10-27 Silicone/dacron composite vascular graft
JP5508635A JPH07505789A (en) 1991-11-04 1992-10-27 Silicone/Dacron composite tube graft
EP92924189A EP0662805A1 (en) 1991-11-04 1992-10-27 Silicone/dacron composite vascular graft

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/787,227 US5866217A (en) 1991-11-04 1991-11-04 Silicone composite vascular graft
US787,227 1991-11-04

Publications (1)

Publication Number Publication Date
WO1993008768A1 true WO1993008768A1 (en) 1993-05-13

Family

ID=25140802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009359 WO1993008768A1 (en) 1991-11-04 1992-10-27 Silicone/dacron composite vascular graft

Country Status (6)

Country Link
US (2) US5866217A (en)
EP (1) EP0662805A1 (en)
JP (1) JPH07505789A (en)
AU (1) AU672588B2 (en)
CA (1) CA2122716A1 (en)
WO (1) WO1993008768A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591226A (en) * 1995-01-23 1997-01-07 Schneider (Usa) Inc. Percutaneous stent-graft and method for delivery thereof
WO2001028456A1 (en) * 1999-10-15 2001-04-26 Edwards Lifesciences Corporation Laminated self-sealing vascular access graft
US9468495B2 (en) 2005-06-20 2016-10-18 Medtronic Ablation Frontiers Llc Ablation catheter

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6102884A (en) 1997-02-07 2000-08-15 Squitieri; Rafael Squitieri hemodialysis and vascular access systems
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6171295B1 (en) * 1999-01-20 2001-01-09 Scimed Life Systems, Inc. Intravascular catheter with composite reinforcement
US6517571B1 (en) 1999-01-22 2003-02-11 Gore Enterprise Holdings, Inc. Vascular graft with improved flow surfaces
US6585760B1 (en) * 2000-06-30 2003-07-01 Vascular Architects, Inc AV fistula and function enhancing method
US6974473B2 (en) 2000-06-30 2005-12-13 Vascular Architects, Inc. Function-enhanced thrombolytic AV fistula and method
US6547820B1 (en) 2000-10-03 2003-04-15 Scimed Life Systems, Inc. High profile fabric graft for arteriovenous access
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US7147617B2 (en) * 2001-11-27 2006-12-12 Scimed Life Systems, Inc. Arterio-venous shunt graft
US6752827B2 (en) 2001-12-04 2004-06-22 Vasca, Inc. Devices, systems, and methods for subcutaneously placing an article
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7288111B1 (en) * 2002-03-26 2007-10-30 Thoratec Corporation Flexible stent and method of making the same
US20030211135A1 (en) * 2002-04-11 2003-11-13 Greenhalgh Skott E. Stent having electrospun covering and method
US20050187605A1 (en) * 2002-04-11 2005-08-25 Greenhalgh Skott E. Electrospun skin capable of controlling drug release rates and method
US20040051201A1 (en) * 2002-04-11 2004-03-18 Greenhalgh Skott E. Coated stent and method for coating by treating an electrospun covering with heat or chemicals
US20030195611A1 (en) * 2002-04-11 2003-10-16 Greenhalgh Skott E. Covering and method using electrospinning of very small fibers
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US6732501B2 (en) * 2002-06-26 2004-05-11 Heartware, Inc. Ventricular connector
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US7452374B2 (en) * 2003-04-24 2008-11-18 Maquet Cardiovascular, Llc AV grafts with rapid post-operative self-sealing capabilities
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
WO2004110304A2 (en) * 2003-05-29 2004-12-23 Secor Medical, Llc Filament based prosthesis
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7762977B2 (en) 2003-10-08 2010-07-27 Hemosphere, Inc. Device and method for vascular access
WO2005044361A1 (en) * 2003-11-07 2005-05-19 Merlin Md Pte Ltd Implantable medical devices with enhanced visibility, mechanical properties and biocompatibility
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
DE602004029092D1 (en) 2003-12-05 2010-10-21 Dexcom Inc CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTIC SENSOR
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7364592B2 (en) * 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
EP1734897A4 (en) 2004-03-31 2010-12-22 Merlin Md Pte Ltd A method for treating aneurysms
US8715340B2 (en) * 2004-03-31 2014-05-06 Merlin Md Pte Ltd. Endovascular device with membrane
SG133420A1 (en) * 2005-12-13 2007-07-30 Merlin Md Pte Ltd An endovascular device with membrane having permanently attached agents
US8500751B2 (en) 2004-03-31 2013-08-06 Merlin Md Pte Ltd Medical device
US7134857B2 (en) * 2004-04-08 2006-11-14 Research Triangle Institute Electrospinning of fibers using a rotatable spray head
US7762801B2 (en) * 2004-04-08 2010-07-27 Research Triangle Institute Electrospray/electrospinning apparatus and method
US7297305B2 (en) 2004-04-08 2007-11-20 Research Triangle Institute Electrospinning in a controlled gaseous environment
US7592277B2 (en) * 2005-05-17 2009-09-22 Research Triangle Institute Nanofiber mats and production methods thereof
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
WO2006026725A2 (en) 2004-08-31 2006-03-09 C.R. Bard, Inc. Self-sealing ptfe graft with kink resistance
US8029563B2 (en) * 2004-11-29 2011-10-04 Gore Enterprise Holdings, Inc. Implantable devices with reduced needle puncture site leakage
WO2006033641A1 (en) * 2004-12-22 2006-03-30 Merlin Md Pte Ltd A medical device
ATE451077T1 (en) * 2005-02-14 2009-12-15 Vascutek Ltd ARTIFICIAL BLOOD VESSEL
US20060257447A1 (en) * 2005-03-09 2006-11-16 Providence Health System Composite graft
DE102005019649A1 (en) * 2005-04-26 2006-11-02 Alveolus Inc. Flexible stent for positioning in lumen of esophagus comprises tube and stabilization members defined circumferentially about tube, where each member extends inwardly in tube to define inner diameter that is less than inner diameter of tube
CA2610896C (en) * 2005-06-17 2014-07-08 C.R. Bard, Inc. Vascular graft with kink resistance after clamping
WO2007002933A2 (en) * 2005-06-28 2007-01-04 Stout Medical Group, Inc. Micro-thin film structures for cardiovascular indications
JP5280852B2 (en) 2005-11-09 2013-09-04 シー・アール・バード・インコーポレーテッド Grafts and stent grafts with radiopaque markers
CA2626601A1 (en) * 2005-11-09 2007-05-18 C.R. Bard Inc. Grafts and stent grafts having a radiopaque beading
US8163002B2 (en) * 2005-11-14 2012-04-24 Vascular Devices Llc Self-sealing vascular graft
US20070167901A1 (en) * 2005-11-17 2007-07-19 Herrig Judson A Self-sealing residual compressive stress graft for dialysis
AU2006338324A1 (en) * 2006-02-13 2007-08-23 Merlin Md Pte Ltd Endovascular device with membrane
WO2007143225A2 (en) 2006-06-07 2007-12-13 Abbott Diabetes Care, Inc. Analyte monitoring system and method
EP2079575B1 (en) * 2006-10-12 2021-06-02 C.R. Bard, Inc. Methods for making vascular grafts with multiple channels
US20100070020A1 (en) * 2008-06-11 2010-03-18 Nanovasc, Inc. Implantable Medical Device
US20100331957A1 (en) * 2007-06-11 2010-12-30 Nanovasc, Inc. Implantable medical device
US8795577B2 (en) 2007-11-30 2014-08-05 Cook Medical Technologies Llc Needle-to-needle electrospinning
US20110295181A1 (en) 2008-03-05 2011-12-01 Hemosphere, Inc. Implantable and removable customizable body conduit
CA2716995C (en) 2008-03-05 2014-11-04 Hemosphere, Inc. Vascular access system
WO2010027363A1 (en) * 2008-09-05 2010-03-11 Merlin Md Pte Ltd Endovascular device
US8262692B2 (en) * 2008-09-05 2012-09-11 Merlin Md Pte Ltd Endovascular device
US20110106242A1 (en) * 2009-10-29 2011-05-05 Po-Jen Ko Artificial blood vessel
US8637109B2 (en) * 2009-12-03 2014-01-28 Cook Medical Technologies Llc Manufacturing methods for covering endoluminal prostheses
EP2544623B1 (en) 2010-03-09 2018-01-10 Solinas Medical Inc. Self-closing devices
WO2012118957A2 (en) * 2011-03-02 2012-09-07 Eskridge Joe Michael Endovascular closure system
CN103813817A (en) 2011-09-06 2014-05-21 海默斯菲尔有限公司 Vascular access system with connector
US9175427B2 (en) 2011-11-14 2015-11-03 Cook Medical Technologies Llc Electrospun patterned stent graft covering
ES2943709T3 (en) 2012-04-06 2023-06-15 Merlin Md Pte Ltd Devices to treat an aneurysm
US10154918B2 (en) 2012-12-28 2018-12-18 Cook Medical Technologies Llc Endoluminal prosthesis with fiber matrix
EP2983625B1 (en) 2013-04-13 2024-02-14 Solinas Medical, Inc. Self-closing devices and apparatus and methods for making and delivering them
WO2015048224A1 (en) * 2013-09-25 2015-04-02 Johnson Jed K Fiber scaffolds for use creating implantable structures
US9814560B2 (en) 2013-12-05 2017-11-14 W. L. Gore & Associates, Inc. Tapered implantable device and methods for making such devices
WO2015094514A1 (en) 2013-12-20 2015-06-25 Cryolife, Inc. Vascular access system with reinforcement member
BR112017025950A2 (en) 2015-06-05 2018-08-14 W. L. Gore & Associates, Inc. ? low bleed implantable prosthesis with a taper?
JP7222881B2 (en) 2016-04-25 2023-02-15 ソリナス メディカル インコーポレイテッド Self-sealing tubular grafts, patches, methods of making and using same
WO2018089625A2 (en) 2016-11-10 2018-05-17 Merit Medical Systems, Inc. Anchor device for vascular anastomosis
WO2018132573A1 (en) 2017-01-12 2018-07-19 Merit Medical Systems, Inc. Methods and systems for selection and use of connectors between conduits
EP3573682A4 (en) 2017-01-25 2020-11-04 Merit Medical Systems, Inc. Methods and systems for facilitating laminar flow between conduits
US11026704B2 (en) 2017-03-06 2021-06-08 Merit Medical Systems, Inc. Vascular access assembly declotting systems and methods
US10925710B2 (en) 2017-03-24 2021-02-23 Merit Medical Systems, Inc. Subcutaneous vascular assemblies for improving blood flow and related devices and methods
WO2019014444A2 (en) 2017-07-14 2019-01-17 Merit Medical Systems, Inc. Releasable conduit connectors
WO2019018653A1 (en) 2017-07-20 2019-01-24 Merit Medical Systems, Inc. Methods and systems for coupling conduits
GB201717885D0 (en) 2017-10-31 2017-12-13 Hothouse Medical Ltd Prothesis and method of manufacture
US11331458B2 (en) 2017-10-31 2022-05-17 Merit Medical Systems, Inc. Subcutaneous vascular assemblies for improving blood flow and related devices and methods
US11027046B2 (en) 2017-10-31 2021-06-08 Hothouse Medical Limited Textile products having selectively applied sealant or coating and method of manufacture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3866247A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Graft tubes
US3890107A (en) * 1972-09-25 1975-06-17 Research Corp Materials useful for prosthetic devices and the like
US4687482A (en) * 1984-04-27 1987-08-18 Scripps Clinic And Research Foundation Vascular prosthesis
US4878908A (en) * 1974-08-05 1989-11-07 Imperial Chemical Industries Plc Fibrillar product
US4986832A (en) * 1987-09-04 1991-01-22 Ube Industries, Ltd. Artificial blood vessel and process for preparing it

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1104680A (en) * 1965-10-18 1968-02-28 Univ Birmingham Artificial artery
US3409914A (en) * 1966-07-01 1968-11-12 Avco Corp Connector for blood pumps and the like
US3713441A (en) * 1970-10-22 1973-01-30 Battelle Development Corp Method of using an artery vein shunt applique
US3866609A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Apparatus for growing graft tubes in place
US3823705A (en) * 1972-12-26 1974-07-16 Dow Corning Blood vessel bridging device
US3929971A (en) * 1973-03-30 1975-12-30 Research Corp Porous biomaterials and method of making same
GB1522605A (en) * 1974-09-26 1978-08-23 Ici Ltd Preparation of fibrous sheet product
US4061134A (en) * 1975-10-28 1977-12-06 Samuels Peter B Arterial graft device
CH632921A5 (en) * 1978-04-06 1982-11-15 Intermedicat Gmbh Method of producing bend-free, elastic, puncture-tight vascular protheses
DE2960875D1 (en) * 1978-04-19 1981-12-10 Ici Plc A method of preparing a tubular product by electrostatic spinning
DE2965672D1 (en) * 1978-10-10 1983-07-21 Ici Plc Production of electrostatically spun products
EP0011437B1 (en) * 1978-11-20 1983-06-22 Imperial Chemical Industries Plc A process for setting a product comprising electrostatically spun fibres, and products prepared according to this process
US4416028A (en) * 1981-01-22 1983-11-22 Ingvar Eriksson Blood vessel prosthesis
US4604762A (en) * 1981-02-13 1986-08-12 Thoratec Laboratories Corporation Arterial graft prosthesis
GB2115776B (en) * 1982-03-02 1986-03-12 Ontario Research Foundation Implantable material
EP0128501B1 (en) * 1983-06-06 1989-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Artificial vessel and process for preparing the same
FR2556210B1 (en) * 1983-12-08 1988-04-15 Barra Jean Aubert VENOUS PROSTHESIS AND PROCESS FOR PRODUCING THE SAME
US4842575A (en) * 1984-01-30 1989-06-27 Meadox Medicals, Inc. Method for forming impregnated synthetic vascular grafts
US4657544A (en) * 1984-04-18 1987-04-14 Cordis Corporation Cardiovascular graft and method of forming same
US5037377A (en) * 1984-11-28 1991-08-06 Medtronic, Inc. Means for improving biocompatibility of implants, particularly of vascular grafts
US4629458A (en) * 1985-02-26 1986-12-16 Cordis Corporation Reinforcing structure for cardiovascular graft
US4990131A (en) * 1987-09-01 1991-02-05 Herbert Dardik Tubular prostheses for vascular reconstructive surgery and process for preparing same
US4906465A (en) * 1987-10-19 1990-03-06 Massachusetts Institute Of Technology Antithrombogenic devices containing polysiloxanes
US4969896A (en) * 1989-02-01 1990-11-13 Interpore International Vascular graft prosthesis and method of making the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3866247A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Graft tubes
US3890107A (en) * 1972-09-25 1975-06-17 Research Corp Materials useful for prosthetic devices and the like
US4878908A (en) * 1974-08-05 1989-11-07 Imperial Chemical Industries Plc Fibrillar product
US4687482A (en) * 1984-04-27 1987-08-18 Scripps Clinic And Research Foundation Vascular prosthesis
US4986832A (en) * 1987-09-04 1991-01-22 Ube Industries, Ltd. Artificial blood vessel and process for preparing it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0662805A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591226A (en) * 1995-01-23 1997-01-07 Schneider (Usa) Inc. Percutaneous stent-graft and method for delivery thereof
US5755775A (en) * 1995-01-23 1998-05-26 Schneider (Usa) Inc. Percutaneous stent-graft and method for delivery thereof
WO2001028456A1 (en) * 1999-10-15 2001-04-26 Edwards Lifesciences Corporation Laminated self-sealing vascular access graft
AU769116B2 (en) * 1999-10-15 2004-01-15 Edwards Lifesciences Corporation Laminated self-sealing vascular access graft
US9468495B2 (en) 2005-06-20 2016-10-18 Medtronic Ablation Frontiers Llc Ablation catheter

Also Published As

Publication number Publication date
JPH07505789A (en) 1995-06-29
AU672588B2 (en) 1996-10-10
AU3059192A (en) 1993-06-07
CA2122716A1 (en) 1993-05-13
US5866217A (en) 1999-02-02
EP0662805A1 (en) 1995-07-19
US5840240A (en) 1998-11-24
EP0662805A4 (en) 1995-03-03

Similar Documents

Publication Publication Date Title
US5840240A (en) Method of making a silicone composite vascular graft
US4712553A (en) Sutures having a porous surface
US5549664A (en) Artificial blood vessel
EP0656196B1 (en) Implantable tubular prosthesis
US4475972A (en) Implantable material
US5383927A (en) Non-thromogenic vascular prosthesis
US7682382B2 (en) Intraluminal lining
JP4401165B2 (en) Composite ePTFE / fiber prosthesis
US5192310A (en) Self-sealing implantable vascular graft
US4905367A (en) Manufacture of stretchable porous sutures
US5061276A (en) Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
EP0698395A1 (en) Tubular polyetrafluoroethylene implantable prosthesis
CA2511364A1 (en) Multi-lumen vascular grafts having improved self-sealing properties
CA2432164A1 (en) Improved vascular prosthesis and method for production thereof
GB2115776A (en) Implantable material
WO1998019632A1 (en) Artificial tubular body organ grafts
EP0495127B1 (en) Artificial blood vessel and production thereof
JPS6316261B2 (en)
CA1169346A (en) Implantable material
JPH04300537A (en) Composite artificial blood vessel
JPH0787850B2 (en) Manufacturing method of artificial prosthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2122716

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992924189

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992924189

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992924189

Country of ref document: EP